Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MRD conversion during oral azacitidine maintenance correlates with outcomes in predominantly favorable-risk AML.

Annals of hematology·2026
Same author

Viral Reactivation in Multiple Myeloma Patients Receiving Anti-BCMA Chimeric Antigen Receptor T-Cell Therapy.

International journal of molecular sciences·2026
Same author

Dysregulated metabolic homeostasis as a unifying death mechanism underlying the diverse clinical manifestations of COVID-19: insights from a retrospective analysis of sequential blood variables.

Frontiers in medicine·2026
Same author

Prognostic Factors, FLT-3 Mutations, and Treatment Outcomes with Pediatric-Inspired Protocols in Adolescent and Young Adults and Adult Patients with Acute Lymphoblastic Leukemia.

Acta haematologica·2025
Same author

Post-Relapse Outcomes of Older Patients With NPM1-Mutated AML Are Favorable With Allo Transplant in Second Remission.

European journal of haematology·2024
Same author

Talin1 dysfunction is genetically linked to systemic capillary leak syndrome.

JCI insight·2024

Related Experiment Video

Updated: Jul 11, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive

Natalie Kronik1, Yuri Kogan, Vladimir Vainstein

  • 1Institute for Medical BioMathematics (IMBM), 10 Hate'ena St., PO Box 282, Bene Ataroth 60991, Israel. natalie@imbm.org

Cancer Immunology, Immunotherapy : CII
|September 8, 2007
PubMed
Summary

Mathematical modeling suggests that adoptive cellular immunotherapy could effectively treat glioblastoma (GBM) if higher doses of activated cytotoxic T-lymphocytes (aCTL) are used. This approach may offer a viable treatment for malignant glioma by personalizing regimens based on tumor characteristics.

More Related Videos

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
08:02

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Published on: March 6, 2012

Related Experiment Videos

Last Updated: Jul 11, 2026

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model
08:02

Combination Radiotherapy in an Orthotopic Mouse Brain Tumor Model

Published on: March 6, 2012

Area of Science:

  • Immunology
  • Mathematical Biology
  • Oncology

Background:

  • Glioblastoma (GBM) is a highly aggressive brain tumor (WHO grade IV) resistant to conventional therapies.
  • Adoptive cellular immunotherapy using ex vivo activated alloreactive cytotoxic T-lymphocytes (aCTL) has shown promise for lower-grade gliomas but failed in GBM.
  • Understanding the complex interactions between tumor cells, immune cells, and signaling molecules is crucial for developing effective GBM treatments.

Purpose of the Study:

  • To develop a mathematical model simulating the interactions between glioma, the immune system, and aCTL immunotherapy.
  • To identify optimal dosing strategies and personalized treatment regimens for malignant glioma, including GBM.
  • To re-evaluate the potential of aCTL immunotherapy for GBM based on computational modeling.

Main Methods:

  • Construction of a mathematical model incorporating dynamics of aCTL, tumor cells, MHC molecules, and cytokines (TGF-beta, IFN-gamma).
  • Computer simulations for model verification against clinical trial data and exploration of treatment scenarios.
  • Analysis of model predictions to identify key biomarkers and personalized treatment parameters.

Main Results:

  • The model accurately reproduced clinical outcomes for aCTL immunotherapy in anaplastic oligodendroglioma and astrocytoma (WHO grade III).
  • Model simulations indicated that previous aCTL immunotherapy failed in GBM due to a 20-fold lower administered dose than required for efficacy.
  • Calculated dose-intensive strategies (e.g., 3 x 10^8 aCTL every 4 days for small tumors, 2 x 10^9 aCTL every 5 days for larger tumors) were predicted to be effective for GBM eradication.

Conclusions:

  • Adoptive cellular immunotherapy for GBM may have been prematurely abandoned and could be efficacious with augmented dose intensity.
  • The mathematical model provides a framework for designing personalized, dose-intensive aCTL immunotherapy regimens for malignant gliomas (grades III-IV).
  • Re-initiation of clinical trials with calculated, individualized regimens is recommended to validate the model's predictions for GBM treatment.